Codiak’s Engineered Exosomes Promote T Cell and Antibody Responses to SARS-CoV-2 in vivo, Supporting the Potential for a Broadly Protective Pan-Beta Coronavirus and Variant Vaccine
December 02, 2021 08:30 ET
|
Codiak BioSciences, Inc.
CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based...
Achiko’s Position on Omicron Variant
December 02, 2021 07:30 ET
|
Achiko AG
The chemical mode of action of AptameX, Achiko's rapid Covid-19 test, strongly suggests that Omicron can be detected as reliably as any other Covid-19 variant known to dateAchiko’s highly effective,...
Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant
December 02, 2021 02:07 ET
|
Vir Biotechnology, Inc.
– Preclinical data demonstrate sotrovimab, authorized in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron – – Data to...
The new Omicron variant: What we know and don’t know
December 01, 2021 05:56 ET
|
University of the Free state
Bloemfontein, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Even though not much is yet known about the new COVID-19 variant, Omicron, the presence of a high number of mutations – more than 30 – in the spike...
First Wave BioPharma Announces Independent Data Monitoring Committee Provides Positive Interim Safety Assessment for Part 2 COVID-19 RESERVOIR Clinical Trial of Niclosamide for the Treatment of Gastrointestinal Infections
November 30, 2021 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Nov. 30, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
AB Science annonce le recrutement du premier patient dans l'étude de phase 2 évaluant l'activité antivirale du masitinib contre le virus SARS-CoV-2 (COVID-19)
November 29, 2021 14:57 ET
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LE RECRUTEMENT DU PREMIER PATIENT DANS l’ETUDE DE PHASE 2 EVALUANT L’ACTIVITE ANTIVIRALE DU MASITINIB CONTRE LE VIRUS SARS-CoV-2 (COVID-19) Paris, 29 novembre...
AB Science announces dosing of first patient in Phase 2 trial of masitinib’s antiviral activity against the SARS-CoV-2 (COVID-19) virus
November 29, 2021 14:57 ET
|
AB Science
PRESS RELEASE AB SCIENCE ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 2 TRIAL OF MASITINIB’S ANTIVIRAL ACTIVITY AGAINST THE SARS-CoV-2 (COVID-19) VIRUS Paris, 29 November, 2021, 8.45pm CET AB Science...